AMAG Pharmaceuticals, Inc.

How to interpret these research links

Connected source records

The exact organization name AMAG Pharmaceuticals, Inc. appears in 5 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials5

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

5 shown

Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe PreeclampsiaNCT03008616 · lead sponsor · 2017-04-12

TERMINATED

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase InhibitorsNCT04493333 · collaborator · 2021-06-07

TERMINATED

Aspirin for the Prevention of Preeclampsia in Women With Stage 1 HypertensionNCT04908982 · collaborator · 2021-05-28

UNKNOWN

Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast CancerNCT03740945 · collaborator · 2018-11-06

WITHDRAWN

Imaging Inflammation in Autoimmune DiabetesNCT00585936 · collaborator · 2007-09-01

COMPLETED

Sponsor roles

collaborator4

lead sponsor1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.